On March 21, 2022 Biond Biologics Ltd., a private, clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, reported that the abstract on BND-67 was accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place on April 8 – 13, 2022, in New Orleans, Louisiana (Press release, Biond Biologics, MAR 21, 2022, View Source [SID1234610498]). BND-67 is a nanobody-based agent that targets CD28 shedding – a novel immune-regulatory mechanism found in cancer patients that serves as a potential resistance mechanism to anti-PD-1 therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Biond will give an oral presentation in the session of: "Experimental and Molecular Therapeutics -Elucidating Disease Biology and Drug Resistance Mechanisms". The presentation title is: "CD28 shedding is a novel resistance mechanism to anti PD-1 therapy", (Abstract #654) and it will be held on Sunday, Apr 10th, 2022, at 3:00PM.
BND-67 Oral Presentation at 2022 AACR (Free AACR Whitepaper) Annual Meeting
Anti-PD-1 drugs dominate the immunotherapy market for a decade now, yet resistance mechanisms to anti-PD-1 therapies remain poorly understood. There are indications that efficient anti-PD-1 therapies rely specifically on intact CD28/B7 signaling. Biond Biologics’ research demonstrated an unknown mechanism for active shedding of membranal CD28 by specific Matrix metalloproteinases (MMPs), upon T cell stimulation in humans. Soluble CD28 produced by this shedding mechanism was shown to counteract the efficacy of anti-PD-1 blocking antibodies in-vitro. In the oral presentation to be given at the AACR (Free AACR Whitepaper), Biond will present data demonstrating CD28-shedding process as a potential resistance mechanism to PD-1 therapies and will describe BND-67, an agent that can selectively and efficiently block this novel regulatory mechanism in cancer patients.
In addition to Biond’s BND-67 program, the company’s Immuno-Oncology (I-O) pipeline also includes BND-35, an anti Ig-Like Transcript 3 (ILT3) antibody, an immune checkpoint inhibitor that inhibits the activity of suppressive myeloid cells. Biond’s clinical I-O program, BND-22 (SAR444881), is an Ig-Like Transcript 2 (ILT2) receptor-blocking antibody that was partnered with Sanofi. BND-22 is in a phase 1 clinical trial in advanced cancer patients with select solid tumor types as monotherapy and in combination with Cetuximab and Pembrolizumab. Biond is also developing INspire, a transformative intracellular delivery platform for biologics, which will allow the targeting of well-known yet hard-to-target intracellular cancer-promoting pathways with biologics.
"The work that will be presented showcases the pioneering research conducted at Biond Biologics utilizing real-world patient and tumor samples, leading to the discovery of novel immune evasion and regulatory mechanisms", said Ilana Mandel, Ph.D., VP R&D at Biond Biologics.
"We’re excited to share at the upcoming AACR (Free AACR Whitepaper) annual meeting, this unique regulatory mechanism discovered at Biond, which can serve as a resistance mechanism to anti-PD-1 treatment. We will also present ways to overcome this mechanism with BND-67, a proprietary nanobody that targets CD28 shedding in cancer patients", added Motti Hakim, Ph.D., Immuno-Oncology director at Biond Biologics.